Search PubMed⌕ Search

Biomedical subjects

V Manninen

Publications and source records attributed to V Manninen.

151 records · Page 9Linked to original sources
PubMedDate not supplied

The triglyceride issue revisited. Findings from the Helsinki Heart Study.

BACKGROUND: In clinical practice, high triglyceride level is recognized as an indicator of increased risk of coronary heart disease (CHD), while most epidemiological studies have shown that triglyceride level is not an independent risk factor for CHD. In an effort to explain this discrepancy we reanalyzed the Helsinki Heart Study data in the light of findings from recent clinical studies related to the insulin resistance syndrome. METHODS: The log-linear modeling technique was used to study the pattern of cross-sectional interdependence of triglyceride level, high-density lipoprotein cholesterol (HDL-C) level, low-density lipoprotein cholesterol level, blood pressure, and blood glucose level. The CHD risk associated with different combinations of levels of triglycerides, HDL-C, and blood pressure was assessed via Cox proportional hazards models. RESULTS: Triglycerides occupied a central role in the pattern of associations of the factors studied; in particular, the associations with HDL-C level, blood pressure, and blood glucose level were without threshold values. The prevalence of high triglyceride level plus low HDL-C level was strongly associated with blood pressure and blood glucose level, while the prevalence of low HDL-C level alone was not. Only the subgroup with both high triglyceride and low HDL-C levels showed a substantial CHD risk, while those with low HDL-C levels alone or high triglyceride levels alone showed a marginal risk. CONCLUSIONS: Our results suggest that triglycerides play a central mediating role in the occurrence of several CHD risk factors, especially those related to the insulin resistance syndrome. Because of these interdependencies, the question of an independent effect of triglycerides is not relevant, and when assessing CHD risk, triglycerides should be considered jointly with HDL-C.

Adult↗
PubMedDate not supplied

Failure of thyroid hormones to maintain the normal lipoprotein pattern in rats after removal of the pituitary gland.

Hypophysectomy was found to increase low density lipoprotein (LDL) cholesterol in rats from 0.18 to 1.18 mmol/l in 1 week, while very low density lipoprotein (VLDL) and high density lipoprotein (HDL) cholesterol decreased simultaneously from 0.08 to 0.03 mmol/l and from 2.12 to 1.01 mmol/l, respectively. Serum total cholesterol levels remained unchanged. Thyroid supplementation (T3 or T4) with doses causing a euthyroid state did not fully correct the lipoprotein pattern. The increase of LDL caused by hypophysectomy was significantly rectified, but the normal level could not be maintained, whilst the HDL level was not at all affected by thyroid hormones. Serum total cholesterol was markedly reduced in all groups with thyroid supplementation, indicating increased cholesterol catabolism. These results suggest that TSH and peripheral thyroid hormones modulate LDL but no effect on HDL could be detected. Other hormones, notably ACTH, growth hormone, lipotropins and gonadotropins are also involved in the control of lipoproteins at the pituitary level. Their exact impact cannot at present be assessed.

Animals↗
PubMedDate not supplied

Effect of phenytoin on serum lipoproteins in middle-aged men.

We assessed the effect of phenytoin on serum lipids and lipoproteins in a group of 20 male volunteers. Nine of the subjects were healthy, and 11 had coronary heart disease. Their mean age was 44 +/- 7 years. Phenytoin was given at daily doses of 200-350 mg for a period of 4-9 months. Serum total cholesterol increased from 6.9 to 8.1 mmoles/liter (p < 0.001), high-density lipoprotein (HDL) cholesterol from 1.02 to 1.14 mmoles/liter (p < 0.05), low-density lipoprotein cholesterol from 5.0 to 5.9 mmoles/liter (p < 0.05), and total triglycerides from 1.9 to 2.4 mmoles/liter (p < 0.05). The ratio of HDL cholesterol to total cholesterol remained unchanged (14.8 vs. 14.1%). The level of apoprotein A-I increased from 145 to 164 mg/dl (p < 0.001), while A-II remained unchanged. Besides drowsiness, for which 1 patient dropped out, no side effects attributable to phenytoin were seen. As an indication of liver microsomal enzyme induction, serum gamma-glutamyltransferase activity was increased in all subjects during phenytoin treatment. These results cast doubt on the clinical usefulness of phenytoin in treating dyslipidemias.

Adult↗
PubMedDate not supplied

Pirmenol in the long-term treatment of chronic ventricular arrhythmias: a placebo-controlled study.

Pirmenol, a new class I antiarrhythmic drug, was given for the treatment of frequent premature ventricular complexes (PVCs) over a 6-month period. Ten patients who had their arrhythmia effectively suppressed by pirmenol in a dose-ranging study were treated with the lowest effective doses in an open investigation. The mean daily doses were 315 mg at the beginning and 340 mg at the end of 6 months. The mean reduction in the frequency of PVC/h remained between 85.5 and 88.6% during 24-h ambulatory electrocardiogram recordings at 1, 3, 5, and 6 months of therapy. With adjustment of the dosage, the predetermined efficacy criteria were fulfilled by eight to 10 patients at each of the four assessments. The PVC/h or repetitive PVC/h frequencies of the patient group did not decline spontaneously within 6 months of treatment, as shown in a placebo control phase. No aggravation of arrhythmias was observed. Side effects in two patients did not prevent prolonged use.

Anti-Arrhythmia Agents↗